Skip to content
Interferon gamma-1b
Actimmune (interferon gamma-1b) is a protein pharmaceutical. Interferon gamma-1b was first approved as Actimmune on 1999-02-25. It is used to treat bacterial infections, brain neoplasms, chronic hepatitis c, colorectal neoplasms, and cryoglobulinemia amongst others in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
neoplasmsD009369
musculoskeletal diseasesD009140
digestive system diseasesD004066
nervous system diseasesD009422
eye diseasesD005128
urogenital diseasesD000091642
cardiovascular diseasesD002318
hemic and lymphatic diseasesD006425
skin and connective tissue diseasesD017437
Show 2 more
Trade Name
FDA
EMA
Actimmune
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Interferon gamma-1b
Tradename
Proper name
Company
Number
Date
Products
Actimmuneinterferon gamma-1bHorizon Therapeutics PublicN-103836 RX1999-02-25
1 products
Labels
FDA
EMA
Brand Name
Status
Last Update
actimmuneBiologic Licensing Application2020-10-12
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
bacterial infections—D001424A49
brain neoplasmsEFO_0003833D001932C71
chronic hepatitis cEFO_0004220D019698B18.2
colorectal neoplasms—D015179—
cryoglobulinemiaEFO_0005846D003449D89.1
essential thrombocythemia—D013920D47.3
hairy cell leukemia—D007943C91.4
hemangioma—D006391D18.0
hepatitis dEFO_0007304D003699—
hepatocellular carcinoma—D006528C22.0
Show 14 more
Agency Specific
FDA
EMA
Expiration
Code
interferon gamma-1b, Actimmune, Horizon Therapeutics Ireland DAC
2107-02-10Orphan excl.
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
66 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Actinic keratosisD055623L57.01410137749
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Basal cell neoplasmsD01829513———3
Basal cell carcinomaD002280—2———2
NeoplasmsD009369C80—1———1
KeratosisD007642—1———1
Hutchinson's melanotic freckleD018327—1———1
Condylomata acuminataD003218EFO_0007147A63.0—1———1
Seborrheic keratosisD017492EFO_0005584L82—1———1
Squamous cell neoplasmsD018307—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
WartsD014860B072————2
Healthy volunteers/patients—2————2
Molluscum contagiosumD008976EFO_0007375B08.11————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameINTERFERON GAMMA-1B
INN—
Description
Actimmune, Betaferon, Extavia (interferon gamma-1b) is a protein pharmaceutical. Interferon gamma-1b was first approved as Actimmune on 1995-11-30. It is used to treat bacterial infections, brain neoplasms, chronic hepatitis c, colorectal neoplasms, and cryoglobulinemia amongst others in the USA. It has been approved in Europe to treat multiple sclerosis.
Classification
Protein
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL1201564
ChEBI ID—
PubChem CID—
DrugBankDB00033
UNII ID—
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Actimmune - Horizon Therapeutics Public
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Actimmune - Intermune
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 278 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
5,195 adverse events reported
View more details